Skip to main content

Scholarship for those diagnosed with Crohn's Disease

This is another scholarship lead I'm simply passing along. If you're an HPS'er with an interest, then you'll have to check it out for yourself. Grin!

UCB is proud to once again offer 30 one-time scholarships of up to $10,000 each in 2011. This opportunity extends to participants diagnosed with Crohn's disease (CD) who are seeking an associate's, undergraduate, or graduate degree, or who are enrolled in a trade school educational program.
This is the sixth year UCB has had the opportunity to support those living with CD with the Crohn's Scholarship Program. The program aims to help these students continue their education and live beyond the boundaries of their disease.
UCB, Inc., is a global biopharmaceutical company committed to developing innovative treatments for inflammatory diseases such as CD. UCB is dedicated to creating unique programs and tools to help people with Crohn’s fulfill their educational ambitions.
We are proud to sponsor a scholarship program that recognizes and rewards your ability to take control of Crohn's—and not allow it to control you.






Do You Qualify?


This program is designed for applicants of any age. An applicant must be:






•A legal resident of the United States


•Diagnosed with Crohn's disease by a physician


•Seeking an associate's, undergraduate, or graduate degree, or enrolled in a trade school educational program


•An individual who demonstrates academic ambition and embraces a way of life that overcomes the boundaries of living with Crohn's disease


•Enrolled in or awaiting acceptance from a United States-based institution of higher education for the fall semester of 2011


Employees of UCB, their immediate family members, and previous Crohn's Scholarship winners are not eligible for this scholarship.


http://www.crohnsandme.com/crohns-scholarship/Default.aspx


Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria